data which showed that the new generic accounted for 10% of the market. In May 2018, the company announced a collaboration with West Virginia University to expose children across West Virginia to STEM educational initiatives. Valsartan recall In 2018, valsartan manufactured by the company was voluntarily recalled due to the detection of trace amounts of N-nitrosodiethylamine (NDEA) which is a probable human carcinogen. Generic Advair approval In January 2019, the FDA announced its approval of the company's Wixela Inhub, the first approved generic version of GlaxoSmithKline's Advair Diskus. Merger with Pfizer's off-patent drug business and name change to Viatris In late July 2019, the company and Pfizer announced that Pfizer would spin off and merge its off-patent medicine division, Upjohn, with Mylan. In November 2019, Mylan & Upjohn announced that the name of the new company would be Viatris. The company continued sales of Mylan's more than 7,500 products, including biosimilars, generics, brand and over-the-counter remedies, with brands including the Epi-Pen, Viagra, Lipitor and Celebrex. The deal was structured as an all-stock, Reverse Morris Trust transaction. Pfizer shareholders owned 57% of the combined new company and Mylan shareholders owned 43%. Stock On February 23, 1973, the company became a public company via an initial public offering (IPO), on the OTC market. In 1976, the stock moved to NASDAQ and in 1986, it moved to the New York Stock Exchange. Acquisition history The following is an illustration of the company's major mergers and acquisitions and historical predecessors: Mylan (Founded 1961) Somerset Pharmaceuticals (Acq 1989) Dow B. Hickam (Acq 1991) Bertek Inc (Acq 1993) UDL Laboratories (Acq 1996) Penederm Inc (Acq 1998) Matrix Laboratories (Acq 2007) Merck KGaA (Generics div.) (Acq 2007) Bioniche Pharma Holdings (Acq 2010) Pfizer Respiratory Delivery Platform (Acq 2011) Agila Specialties (Acq 2013) Abbott Laboratories (Generics div.) (Acq 2014) Famy Care (Acq 2014) Meda (Acq 2016) Renaissance Acquisition Holdings (Dermatology div.) (Acq 2016) Criticism EpiPen pricing Mylan acquired the right to market and distribute the EpiPen line of epinephrine autoinjector devices from Merck KGaA as part of their 2007 deal; that right had formerly been held by Dey LP, a wholly owned subsidiary of Merck. According to Bloomberg the devices deliver about $1 worth of drug. At that time annual sales were around $200M. Bresch, the company's CEO, saw an opportunity to increase sales through marketing and advocacy, and the company launched a marketing campaign to increase awareness